Published in Ann Neurol on February 01, 1991
Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain (2008) 3.05
Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. BMJ (2006) 2.95
Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry (1994) 1.98
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry (1996) 1.02
Diagnostic value of paraclinical tests in multiple sclerosis: relative sensitivities and specificities for reclassification according to the Poser committee criteria. J Neurol Neurosurg Psychiatry (1995) 0.88
Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol (2007) 0.86
Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology (2011) 0.84
Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis. J Neurol Neurosurg Psychiatry (1993) 0.83
A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry (1996) 0.83
Disease-modifying Therapies for Multiple Sclerosis. Curr Treat Options Neurol (2003) 0.81
Clinical Profiles and Short-Term Outcomes of Acute Disseminated Encephalomyelitis in Adult Chinese Patients. J Clin Neurol (2016) 0.81
MRI demonstration of an anterolateral plaque at C1: a note on some sensory changes including analgesia. J Neurol Neurosurg Psychiatry (1993) 0.78
Serum biomarker gMS-Classifier2: predicting conversion to clinically definite multiple sclerosis. PLoS One (2013) 0.75
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Underenumeration in the 1991 census. BMJ (1993) 1.71
Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome. Ann Neurol (1993) 1.71
Adaptation of the nitrate reductase and Griess reaction methods for the measurement of serum nitrate plus nitrite levels. Ann Clin Biochem (1997) 1.63
Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology (2001) 1.58
Isoelectric focusing versus quantitative measurements in the detection of intrathecal local synthesis of IgG. Clin Chim Acta (1990) 1.45
Oligoclonal immunoglobulins and plasma cells in spinal fluid of patients with multiple sclerosis. Br Med J (1979) 1.41
Inactivation of metronidazole by aerobic organisms. J Antimicrob Chemother (1979) 1.41
Lack of serum oligoclonal antibody responses to Chlamydophila pneumoniae in multiple sclerosis. Eur Neurol (2005) 1.38
Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology (2002) 1.38
A quantitative technique for growing human adult skeletal muscle in culture starting from mononucleated cells. J Neurol Sci (1977) 1.32
Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (2001) 1.30
Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors. Ann Surg (1976) 1.26
Markers for gene expression in cultured cells from the nervous system. J Biol Chem (1972) 1.26
A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods (2003) 1.24
Blood-brain barrier damage in patients with bacterial meningitis: association with tumor necrosis factor-alpha but not interleukin-1 beta. J Infect Dis (1992) 1.20
A rapid method for detecting oligoclonal IgG in unconcentrated CSF, by agarose isoelectric focusing, transfer to cellulose nitrate and immunoperoxidase staining. J Neuroimmunol (1983) 1.19
Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett (1999) 1.17
Herpes simplex encephalitis: an audit of the use of laboratory diagnostic tests. QJM (2004) 1.15
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain (2002) 1.13
Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler (2005) 1.11
Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report. Lancet (1982) 1.09
Isoelectric focusing of cerebrospinal fluid immunoglobulin G: an annotated update. Ann Clin Biochem (1990) 1.08
Axonal damage and outcome in subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry (2006) 1.08
Cerebrospinal fluid ferritin in brain necrosis: evidence for local synthesis. Clin Chim Acta (1993) 1.07
Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain (1997) 1.07
New ultramicromethod for concentration of cerebrospinal fluid. Lancet (1976) 1.07
An ELISA for glial fibrillary acidic protein. J Immunol Methods (2004) 1.07
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry (2005) 1.07
Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. Ann Neurol (2001) 1.06
Double-blind, controlled trial of immunosuppression in treatment of multiple sclerosis. Lancet (1980) 1.06
Laboratory diagnosis of multiple sclerosis: immunological and biochemical aspects. Br Med Bull (1977) 1.06
Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J Immunol (1998) 1.05
Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet's disease involving the nervous system. J Neurol Neurosurg Psychiatry (1995) 1.04
Evidence for increased nitric oxide production in multiple sclerosis. J Neurol Neurosurg Psychiatry (1995) 1.03
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology (2004) 1.03
A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry (1996) 1.02
Free light chains in the cerebrospinal fluid: an indicator of recent immunological stimulation. J Neurol Neurosurg Psychiatry (1985) 1.02
In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol (1992) 1.02
Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease. Sex Transm Infect (2000) 1.01
Antibody synthesis within the central nervous system: comparisons of CSF IgG indices and electrophoresis. J Clin Pathol (1983) 1.00
A specific and sensitive ELISA for measuring S-100b in cerebrospinal fluid. J Immunol Methods (1997) 0.99
Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neurosci Lett (2003) 0.99
Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage. J Neuroimmunol (1993) 0.98
Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis. J Neurol (2001) 0.98
Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern. Brain Res Bull (2003) 0.97
Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol (2003) 0.97
Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult Scler (2004) 0.97
Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology (2003) 0.97
The potential role of nitric oxide in multiple sclerosis. Mult Scler (1998) 0.96
On the role of glial cells in the mammalian nervous system. Uptake, excretion, and metabolism of putative neurotransmitters by cultured glial tumor cells. J Biol Chem (1974) 0.96
Age-related changes in cerebrospinal fluid protein concentrations. J Neurol Sci (1991) 0.95
A micro-method for measuring total protein in cerebrospinal fluid by using benzethonium chloride in microtiter plate wells. Clin Chem (1989) 0.94
The spectrum of antineuronal autoantibodies in a series of neurological patients. J Neurol Sci (2004) 0.93
Affinity distributions of antigen-specific IgG in patients with multiple sclerosis and in patients with viral encephalitis. J Immunol Methods (1990) 0.93
Detection of 14-3-3 brain protein in cerebrospinal fluid of HIV infected patients. Sex Transm Infect (2000) 0.93
Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler (2005) 0.92
Electrophoresis of CSF proteins. Br J Hosp Med (1982) 0.92
Transport of neurotransmitter precursors into cultured cells. Nat New Biol (1973) 0.92
Intrathecal immunoglobulin M synthesis in multiple sclerosis. Relationship with clinical and cerebrospinal fluid parameters. Brain (1991) 0.92
Sphingolipids and phospholipids in microsomes and myelin from normal and pathological brains. J Neurochem (1968) 0.91
Nitrocellulose immunofixation following agarose electrophoresis in the study of immunoglobulin G subgroups in unconcentrated cerebrospinal fluid. Clin Chim Acta (1982) 0.91
Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury. J Neurol Sci (2003) 0.91
Viral immunoblotting: a sensitive method for detecting viral-specific oliogoclonal bands in unconcentrated cerebrospinal fluid. Biosci Rep (1984) 0.90
Sequential changes in oligoclonal patterns during the course of multiple sclerosis. J Neurol Neurosurg Psychiatry (1983) 0.90
Coccidiosis in kiwis. N Z Vet J (1978) 0.89
115 patients with first cadaver kidney transplants followed two to seven and a half years. A multifactorial analysis. Am J Med (1977) 0.88
Improved detection of oligoclonal and Bence-Jones proteins by kappa/lambda immunoblotting. Clin Chim Acta (1984) 0.88
The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers. Mult Scler (2006) 0.88
Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: a pilot study. Crit Care Med (2002) 0.88
Balancing the Th1/Th2 concept in multiple sclerosis. Immunol Today (1998) 0.88
Isolation and characterization of a new adenovirus serotype from a yearling heifer with systemic infection. N Z Vet J (1980) 0.87
Distribution of cerebrospinal fluid oligoclonal IgM bands in neurological diseases: a comparison between agarose electrophoresis and isoelectric focusing. J Neurol Sci (1992) 0.87
Axonal pathology in subarachnoid and intracerebral hemorrhage. J Neurotrauma (2005) 0.87
Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry (1996) 0.87
Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: a correlation with blood-brain-barrier dysfunction. J Neurol Sci (1998) 0.87
B cell development and regulation after T cell-depleted marrow transplantation. J Immunol (1987) 0.86
I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology (1999) 0.86
Interaction of di-iodinated 125I-labelled alpha-bungarotoxin and reversible cholinergic ligands with intact synaptic acetylcholine receptors on isolated skeletal-muscle fibres from the rat. Biochem J (1979) 0.86
Affinity of antigen-specific IgG distinguishes multiple sclerosis from encephalitis. J Neurol Sci (1995) 0.86
Heightened intrathecal release of proinflammatory cytokines in Creutzfeldt-Jakob disease. Neurology (1999) 0.86
The prevalence of oligoclonal bands in the CSF of patients with primary neurodegenerative dementia. J Neurol (2004) 0.85
Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci Lett (1997) 0.85
Oxidative metabolism of 1-(2-chloroethyl)-3-alkyl-3- (methylcarbamoyl)triazenes: formation of chloroacetaldehyde and relevance to biological activity. Chem Res Toxicol (1996) 0.85
Measurement of the rate and velocity of movement by single heart cells in culture. Am J Cardiol (1973) 0.85
Antigenic differences between neurological and diabetic patients with anti-glutamic acid decarboxylase antibodies. Eur J Neurol (2005) 0.85
Viral specific IgG and IgM antibodies in the CSF of patients with tropical spastic paraparesis. J Neurol (1989) 0.85
Local synthesis of specific IgG in the cerebrospinal fluid of patients with neurosarcoidosis detected by antigen immunoblotting using Kveim material. J Neurol Sci (1990) 0.85
Raised serum nitrate and nitrite levels in patients with multiple sclerosis. J Neurol Sci (1997) 0.85
Neospora abortion in New Zealand cattle. N Z Vet J (1991) 0.84
Tissue culture of dystrophic muscle cells. Br Med Bull (1980) 0.84
Protein adsorption to hydrocephalus shunt catheters: CSF protein adsorption. J Neurol Neurosurg Psychiatry (1998) 0.84
Assessment of cerebrospinal fluid immunoglobulin patterns after isoelectric focusing. Use of kappa and lambda light chain immunoperoxidase staining. J Neurol Sci (1983) 0.84
A quantitative procedure for the dissociation of adult mammalian muscle into mononucleated cells. Exp Cell Res (1976) 0.84
Observations of cat leprosy. N Z Vet J (1979) 0.84
Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis. J Neurol Neurosurg Psychiatry (1993) 0.83
Non-specific seroreactions against Brucella abortus in ruminants in New Zealand and the presence of Yersinia enterocolitica 0:9. N Z Vet J (1995) 0.83
Thy 1 (theta) antigen on the surface of morphologically distinct brain cell types. Cell (1975) 0.83